Home / Recalls / Lupin Pharmaceuticals Inc. / D-0875-2022

D-0875-2022 Class II Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

Recall Details

Product Type
Drugs
Report Date
May 25, 2022
Initiation Date
April 27, 2022
Termination Date
April 13, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
26,910 bottles

Product Description

GaviLyte -C (Polyethylene Glycol 3350, 240 g) and electrolytes for Oral Solution, USP with flavor pack NDC# 43386-060-19

Reason for Recall

Failed Stability Specification

Distribution Pattern

Product was distributed nationwide, including Puerto Rico.

Code Information

Lot # S001132, exp. date July 2022 NDC # 43386-060-19

Other recalls by Lupin Pharmaceuticals Inc.

  • D-0220-2026 Class II — Ganirelix Acetate Injection, 250 mcg/0.5mL, Single-dose Sterile Prefilled Syring (November 13, 2025)
  • D-0227-2026 Class II — Sertraline Hydrochloride Tablets USP, 100 mg, 90 Tablets bottles, Rx Only, Manuf (November 5, 2025)
  • D-0542-2025 Class II — Amlodipine and Benazepril HCl Capsules USP 2.5 mg/10 mg, 100 Capsules bottle, Rx (July 2, 2025)
  • D-0537-2025 Class II — clomiPRAMINE Hydrochloride Capsules USP 25 mg, 100 count bottles, 5801 Pelican B (June 27, 2025)
  • D-0532-2025 Class II — Lisinopril and Hydrochlorothiazide Tablets USP 20mg/12.5mg, 100-count bottles, R (June 20, 2025)
  • D-0377-2025 Class II — clomiPRAMINE hydrochloride Capsules USP, 25 mg, 100-count bottle, Rx only, Manuf (April 10, 2025)
  • D-0167-2025 Class II — Levothyroxine Sodium Tablets, Lupin, 75 mcg (0.075mg), 1000 Tablets, Rx Only, Ma (December 20, 2024)
  • D-0054-2025 Class II — Ramipril Capsules USP 10 mg, a) 90 count (NDC 68180-591-09), b) 100 count NDC 68 (October 23, 2024)
  • D-0053-2025 Class II — Ramipril Capsules USP 5 mg, a) 90 count (NDC 68180-590-09), b) 100 count NDC 681 (October 23, 2024)
  • D-0052-2025 Class II — Ramipril Capsules USP 2.5 mg, a) 90 count (NDC 68180-589-09), b) 100 count NDC 6 (October 23, 2024)